{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:09:30Z","timestamp":1772262570361,"version":"3.50.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:p>Tildrakizumab is a monoclonal antibody targeting interleukin-23 that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions. While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited. We report real-world drug survival of tildrakizumab in the routine clinical setting.<\/jats:p>","DOI":"10.1093\/ced\/llaf342","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:27:06Z","timestamp":1753702026000},"page":"2496-2497","source":"Crossref","is-referenced-by-count":3,"title":["Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicentre retrospective study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"first","affiliation":[{"name":"Department of Dermatology, Santo Ant\u00f3nio Central Hospital , Porto ,","place":["Portugal"]},{"name":"Institute of Biomedical Sciences Abel Salazar, University of Porto , Porto ,","place":["Portugal"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-5961","authenticated-orcid":false,"given":"Siddhartha","family":"Sood","sequence":"additional","affiliation":[]},{"given":"Orhan","family":"Yilmaz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-2724","authenticated-orcid":false,"given":"Ronald B","family":"Vender","sequence":"additional","affiliation":[]},{"given":"Vimal\u00a0H","family":"Prajapati","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jose-Manuel","family":"Carrascosa","sequence":"additional","affiliation":[]},{"given":"Esteban","family":"Dauden","sequence":"additional","affiliation":[]},{"given":"Mar","family":"Llamas-Velasco","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[]},{"given":"Barbara Guerra","family":"Leal","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences Abel Salazar, University of Porto , Porto ,","place":["Portugal"]}]},{"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[]},{"given":"Gianmarco","family":"Silvi","sequence":"additional","affiliation":[]},{"given":"Eugenia\u00a0Veronica","family":"Di\u00a0Brizzi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-0592","authenticated-orcid":false,"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Sechi","sequence":"additional","affiliation":[]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[]},{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Del-Alcazar","sequence":"additional","affiliation":[]},{"given":"Asfandyar","family":"Mufti","sequence":"additional","affiliation":[]},{"given":"Lara Valeska","family":"Maul","sequence":"additional","affiliation":[]},{"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-1545","authenticated-orcid":false,"given":"Julia-\u00a0Tatjana","family":"Maul","sequence":"additional","affiliation":[]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2025112512414746600_llaf342-B1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s40265-018-0917-3","article-title":"Tildrakizumab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"2025112512414746600_llaf342-B2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"2025112512414746600_llaf342-B3","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025112512414746600_llaf342-B4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025112512414746600_llaf342-B5","doi-asserted-by":"crossref","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses \u2013\u200c IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf342\/63870262\/llaf342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2496\/63870262\/llaf342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/12\/2496\/63870262\/llaf342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:41:53Z","timestamp":1764092513000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/12\/2496\/8215858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":5,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf342","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,29]]}}}